Epidemiological characteristics, medical costs and healthcare resource utilization of diabetes-related complications among Chinese patients with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

Epidemiological characteristics, medical costs and healthcare resource utilization of diabetes-related complications among Chinese patients with type 2 diabetes mellitus

Published:2019-09-03 Issue:5 Volume:20 Page:513-521
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Duan Xiaotuo¹,Li Yunguang²,Liu Qingjing³,Liu Li⁴,Li Chaoyun⁴

Affiliation:

1. Health Economics and Outcome Research, Beijing Brainpower Pharma Consulting Co. Ltd, Beijing, China

2. Medical Department, Sanofi, Shanghai, China

3. Beijing North Medical & Health Economic Research Center, Beijing, China

4. Health Economics and Outcome Research, Sanofi, Shanghai, China

Funder

Sanofi China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2019.1661777

Reference27 articles.

1. Global estimates of the prevalence of diabetes for 2010 and 2030

2. Diabetes care in figures: current pitfalls and future scenario

3. Global estimates of diabetes prevalence for 2013 and projections for 2035

4. Standards of care for type 2 diabetes in China

5. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of Finerenone in Addition to Standard of Care for Patients with Chronic Kidney Disease and Type 2 Diabetes in China;Advances in Therapy;2024-06-16

2. Ethanol extract of Alpiniae oxyphyllae fructus regulates glucose metabolism, the HPA axis and hippocampal function in diabetic mice with depression;2023-11-08

3. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients;Diabetology & Metabolic Syndrome;2023-08-19

4. Potential health and economic impact associated with achieving risk factor control in Chinese adults with diabetes: a microsimulation modelling study;The Lancet Regional Health - Western Pacific;2023-04

5. Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China;Diabetes Therapy;2022-11-22